PET/CT scans were performed using a small-animal bench-top PET/CT scanner (G8, Perkin Elmer, MA, USA; Additional file
1). Mice were injected intravenously with
152Tb-PSMA-617 (10 MBq, 1 nmol, 100 μL, diluted in saline) and anesthetized with a mixture of isoflurane and oxygen for in vivo scans (PET/CT and SPECT/CT). Static whole-body PET scans, 10 min in duration, were performed at 2 and 15 h p.i. of the radioligand, followed by a CT scan of 1.5 min. SPECT/CT studies were performed using a small-animal SPECT/CT scanner (
NanoSPECT/CTTM, Mediso Medical Imaging Systems, Budapest, Hungary) (Additional file
1). Tumor-bearing mice were intravenously injected with
177Lu-PSMA-617 (25 MBq, 1 nmol, 100 μL, diluted in saline). Static SPECT/CT scans, 45 min in duration, were performed at 2 h and 15 h p.i. of the radioligand, followed by a CT scan of 7.5 min. Reconstruction of the acquired data was performed using the software of the scanner in question. All images were prepared using
VivoQuant post-processing software (version 3.5, inviCRO Imaging Services and Software, Boston, USA). A Gauss post-reconstruction filter (full width at half maximum = 1 mm) was applied to the images and the scale adjusted by cutting 5% of the lower signal intensity to make the tumors and kidneys readily visible.
Müller C., Singh A., Umbricht C.A., Kulkarni H.R., Johnston K., Benešová M., Senftleben S., Müller D., Vermeulen C., Schibli R., Köster U., van der Meulen N.P, & Baum R.P. (2019). Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Research, 9, 68.